Meet the BillionToOne team at AACR
Northstar is heading to the AACR Annual Meeting this April, and we’d love to connect with you while we’re there. Whether you’re interested in learning more about our precision oncology platform, meeting the team, or joining us for dinner—complete the form and we’ll be in touch.
© 2025 BillionToOne, Inc. all rights reserved
Northstar is a precision oncology platform from BillionToOne that delivers actionable insights from a single blood sample. With industry-leading sensitivity, Northstar brings clarity to complex cancer care—helping clinicians navigate treatment with confidence.
Developed by the team behind BillionToOne’s molecular diagnostics, Northstar is designed to make advanced cancer testing more accessible, more precise, and more personal.
About Northstar
Our proprietary Quantitative Counting Templates, or QCTs™, power our ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. Several common and severe recessive conditions screened for prenatally can be caused by single-base pair alterations.
Our QCT technology enables quantifying these tiny variations using cell-free DNA. We believe this quantification will open the door to exponential improvements in prenatal screening, liquid biopsy, and beyond.
